The aim of the current review was to present the results of clinical trials on the influence of metformin on circulating cancer-related biomarkers and metabolic factors including insulin, fasting blood sugar (FBS), homeostatic model assessment for insulin resistance (HOMA-IR), body mass index (BMI), and Ki-67. Here, MKI67 is linked to cancer.